| [1] |
周奉, 李同心, 杨松, 等. 结核病短程治疗方案的研究进展. 中国防痨杂志, 2023, 45(3):311-317. doi:10.19982/j.issn.1000-6621.20220447.
|
| [2] |
Guo J, Liu R, Shi J, et al. Rarity of rpoB Mutations Outside the Rifampicin Resistance-Determining Region of Mycobacterium tuberculosis Isolates from Patients Responding Poorly to First-Line Tuberculosis Regimens in Beijing, China: A Retrospective Study. Infect Drug Resist, 2021, 14:2607-2612. doi:10.2147/IDR.S313717.
|
| [3] |
Liu D, Huang F, Zhang G, et al. Whole-genome sequencing for surveillance of tuberculosis drug resistance and determination of resistance level in China. Clin Microbiol Infect, 2022, 28(5):731.e9-731.e15. doi:10.1016/j.cmi.2021.09.014.
|
| [4] |
World Health Organization. Technical report on critical concentrations for drug susceptibility testing of isoniazid and the Rifamycins (Rifampicin, Rifabutin and Rifapentine). Geneva: World Health Organization, 2021.
|
| [5] |
王希江, 谭云洪, 贺文从, 等. 结核分枝杆菌中利福平和异烟肼耐药相关基因突变与耐药水平的相关性研究. 中国防痨杂志, 2021, 43(3):248-254. doi:10.3969/j.issn.1000-6621.2021.03.010.
|
| [6] |
Pang Y, Lu J, Wang Y, et al. Study of the rifampin monoresistance mechanism in Mycobacterium tuberculosis. Antimicrob Agents Chemother, 2013, 57(2):893-900. doi:10.1128/AAC.01024-12.
pmid: 23208715
|
| [7] |
胡族琼, 刘燕文, 周文, 等. 结核分枝杆菌rpoB基因突变特征与利福平耐药水平关系的研究. 中国人兽共患病学报, 2016, 32(1):39-50. doi:10.3969/j.issn.1002-2694.2016.01.009.
|
| [8] |
Li MC, Lu J, Lu Y, et al. rpoB Mutations and Effects on Rifampin Resistance in Mycobacterium tuberculosis. Infect Drug Resist, 2021, 14:4119-4128. doi:10.2147/IDR.S333433.
|
| [9] |
Solo ES, Nakajima C, Kaile T, et al. Mutations in rpoB and katG genes and the inhA operon in multidrug-resistant Mycobacterium tuberculosis isolates from Zambia. J Glob Antimicrob Resist, 2020, 22(9):302-307. doi:10.1016/j.jgar.2020.02.026.
|
| [10] |
Clinical and laboratory standards Institute. Performance Standards for Susceptibility Testing of Mycobacteria, Nocardia spp., and Other Aerobic Actinomycetes. Wayne: Clinical and laboratory standards Institute, 2023.
|
| [11] |
Shea J, Halse TA, Kohlerschmidt D, et al. Low-level rifampin resistance and rpoB mutations in Mycobacterium tuberculosis: an analysis of whole-genome sequencing and drug susceptibility test data in New York. J Clin Microbiol, 2021, 59: e01885-20. doi:10.1128/JCM.01885-20.
|
| [12] |
World Health Organization. Catalogue of mutations in Mycobacterium tuberculosis complex and their association with drug resistance,2nd ed. Geneva: World Health Organization, 2023.
|
| [13] |
张洁, 任怡宣, 潘丽萍, 等. 全基因组测序在结核分枝杆菌研究中的应用. 中国防痨杂志, 2020, 42(7):737-740. doi:10.3969/j.issn.1000-6621.2020.07.017.
|
| [14] |
李相辰, 柳正卫, 陆烨玮, 等. 结核分枝杆菌全基因组测序数据分析方法与应用进展. 中国防痨杂志, 2022, 44(11):1193-1198. doi:10.19982/j.issn.1000-6621.20220219.
|
| [15] |
梅金周, 王云霞, 张梅娟, 等. 全基因组测序技术在耐药肺结核诊断中的应用性评价. 新发传染病电子杂志, 2024, 9(3):16-20. doi:10.19871/j.cnki.xfcrbzz.2024.03.004.
|
| [16] |
蒋燕成, 张建明, 陈紫萱, 等. 结核分枝杆菌耐药基因突变特征及与耐药水平关系的研究. 检验医学与临床, 2023, 20(15):2145-2148. doi:10.3969/j.issn.1672-9455.2023.15.001.
|
| [17] |
杨慧娟, 陈连勇, 茹浩浩, 等. 云南省结核分枝杆菌利福平耐药基因rpoB突变特征分析. 中华疾病控制杂志, 2018, 22(2):147-152. doi:10.16462/j.cnki.zhjbkz.2018.02.011.
|
| [18] |
董春萍, 伍定辉. 厦门地区结核病患者对利福平与异烟肼的耐药情况及其耐药基因突变位点分析. 抗感染药学, 2024, 21(5):487-490. doi:10.13493/j.issn.1672-7878.2024.05-010.
|
| [19] |
赵竟男, 夏辉, 江友桥, 等. 江西省利福平及异烟肼耐药结核分枝杆菌的耐药基因分子特征. 现代预防医学杂志, 2024, 51(13):2460-2465. doi:10.20043/j.cnki.MPM.202404144.
|
| [20] |
Makhado NA, Matabane E, Faccin M, et al. Outbreak of multidrug-resistant tuberculosis in South Africa undetected by WHO-endorsed commercial tests: an observational study. Lancet Infect Dis, 2018, 18(12):1350-1359. doi:10.1016/S1473-3099(18)30496-1.
pmid: 30342828
|
| [21] |
Levin-Reisman I, Ronin I, Gefen O, et al. Antibiotic tolerance facilitates the evolution of resistance. Science, 2017, 355(6327):826-830. doi:10.1126/science.aaj2191.
pmid: 28183996
|
| [22] |
Brauner A, Fridman O, Gefen O, et al. Distinguishing between resistance, tolerance and persistence to antibiotic treatment. Nat Rev Microbiol, 2016, 14(5):320-330. doi:10.1038/nrmicro.2016.34.
pmid: 27080241
|
| [23] |
李勤静, 焦伟伟. 结核分枝杆菌利福平耐药机制及其适应性研究进展. 结核病与肺部健康杂志, 2017, 6(2):106-109. doi:10.3969/j.issn.2095-3755.2017.02.005.
|
| [24] |
Ma P, Luo T, Ge L, et al. Compensatory effects of M.tuberculosis rpoB mutations outside the rifampicin resistance-determining region. Emerg Microbes Infect, 2021, 10(1):743-752. doi:10.1080/22221751.2021.1908096.
|
| [25] |
Li QJ, Jiao WW, Yin QQ, et al. Compensatory Mutations of Rifampin Resistance Are Associated with Transmission of Multidrug-Resistant Mycobacterium tuberculosis Beijing Genotype Strains in China. Antimicrob Agents Chemother, 2016, 60(5):2807-2812. doi:10.1128/AAC.02358-15.
|
| [26] |
叶婧, 周崇兴, 林玫, 等. 广西边境地区与非边境地区结核分枝杆菌基因组学分析. 热带病与寄生虫学, 2023, 21(2):82-87. doi:10.3969/j.issn.1672-2302.2023.02.005.
|
| [27] |
Liu QY, Ma AJ, Wei LH, et al. China’s tuberculosis epidemic stems from historical expansion of four strains of Mycobacterium tuberculosis. Nat Ecol Evol, 2018, 2(12):1982-1992. doi:10.1038/s41559-018-0680-6.
|
| [28] |
张书, 雷卉, 王为娜, 等. 2020—2021年凉山州4个彝族聚居县297株结核分枝杆菌耐药及菌株谱系分析. 预防医学情报杂志, 2024, 40(12):1590-1598. doi:10.19971/j.cnki.1006-4028.230601.
|